Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

MedMira Inc V.MIR

Alternate Symbol(s):  MMIRF

MedMira Inc. is a Canada-based developer and manufacturer of Rapid Vertical Flow (RVF) diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as human immunodeficiency virus (HIV), syphilis, hepatitis, and SARS-CoV-2, in three steps. The Company is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. Its research is focused on specific areas of the broader diagnostics market, namely the rapid, point-of-care, and in vitro sectors. Its tests are sold globally under the REVEAL, REVEALCOVID-19, Multiplo and Miriad brands. Based on its patented Rapid Vertical Flow Technology, the Company's rapid HIV test has regulatory approvals in Canada, the United States, China and the European Union. Its manufacturing facilities are located in Halifax, Nova Scotia, Canada. It provides access to its RVF Technology for researchers, developers, and biotech companies on a license basis.


TSXV:MIR - Post by User

<< Previous
Bullboard Posts
Next >>
Post by reyesingupon Dec 17, 2020 4:33pm
126 Views
Post# 32130830

I think MedMira's test is more important than ever:

I think MedMira's test is more important than ever:


Vaccination, in general, is a very effective way to educate our immune system on the
unique invader features (i.e. pathogen-specific antigens) and promote the production of
immune system soldiers (i.e. specific antibodies).
Usually, the presence of these specific antibodies indicates that the immune response
will happen much faster, and the individual may not exhibit any symptoms or may have
diminished symptom presentation. Protection from SARS-CoV-2, however, still remains
uncertain, with the antibody persistence and potency being not clearly defined. To
evaluate the overall presence of virus-fighting antibodies and aid in the scientific efforts
to establish the biological concept of immune response to SARS-CoV-2, serological
antibody tests are of great importance.
Rapid qualitative antibody tests (such as MedMira’s REVEALCOVID-19TM Total
Antibody Test), in particular, should not be overlooked, as they are time-efficient (results
can be seen as early as 3 minutes after sample addition); not labour intensive; and can
be performed in the variety of environments (no special instruments or power source
are generally required). During the COVID-19 pandemic, time is of the essence, and,
with multiple SARS-CoV-2 vaccines being now administered around the globe, the
future of antibody testing looks more promising than ever!
<< Previous
Bullboard Posts
Next >>